Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 1(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06834074Unknown

Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

Role: lead

NCT06765109Phase 3Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Role: lead

NCT06521554Phase 1Recruiting

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Role: lead

NCT06797362Unknown

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

Role: lead

NCT05384626Phase 1Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Role: lead

NCT05118789Phase 1Recruiting

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Role: lead

All 6 trials loaded